# Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Study · id `cardio:ct-nct07001800` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07001800](<https://clinicaltrials.gov/study/NCT07001800>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07001800

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1276 participants.

## Technical summary

Registry record NCT07001800. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-27 (actual); primary completion 2028-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 1276 participants (planned count; ClinicalTrials.gov record NCT07001800, source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)
- Started: 2025-06-27 (actual) (ClinicalTrials.gov record NCT07001800, source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2028-08-31 (anticipated) (ClinicalTrials.gov record NCT07001800, source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)
- Completion: 2030-09-30 (anticipated) (ClinicalTrials.gov record NCT07001800, source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT07001800, source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07001800-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- Acronym: KATALYST-AV
- Condition: Moderate Aortic Valve Stenosis
- Intervention (Drug): Ataciguat
- Intervention (Drug): Placebo
- Lead sponsor: Kardigan, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Kardigan, Inc. (`cardio:org-kardigan-inc`)

## Provenance

Content hash: e1e8f67173a52139da5cc2dc0b990ad7f1b069ae62eda2c111c389c678834eb7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
